Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates

Transfusion

Volumn 53, Issue 5, 2013, Pages 1143-1144

  Soucie, J Michael ^a   Monahan, Paul E ^b   Kulkarni, Roshni ^c   De Staercke, Christine ^a   Recht, Michael ^d   Chitlur, Meera B ^e   Gruppo, Ralph ^f   Hooper, W Craig ^g   Kessler, Craig ^h   Manco Johnson, Marilyn J ⁱ   Powell, Jerry ^j   Pyle, Meredith ^a   Riske, Brenda ^b   Sabio, Hernan ^j   Trimble, Sean ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j WAKE FOREST UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR CONCENTRATE; PROTHROMBIN COMPLEX;

BLEEDING DISORDER; HUMAN; HUMAN PARVOVIRUS B19; LETTER; NANOFILTRATION; NONHUMAN; NUCLEIC ACID ANALYSIS; PARTICLE SIZE; PORCINE PARVOVIRUS; PREVALENCE; PRODUCT SAFETY; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS LOAD; VIRUS TRANSMISSION;

BLOOD COAGULATION FACTORS; FEMALE; HEMOPHILIA A; HUMANS; MALE; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

EID: 84877693991     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12153     Document Type: Letter

References (5)

1. Gajardo R, Roth NJ, Lee DC, Jorquera JI,. Absence of evidence of parvovirus B19 transmission by plasma-derived clotting concentrates derived from B19V NAT tested plasma and including effective steps for the inactivation/removal of non-enveloped viruses [letter]. Transfusion 2013; 53: 1143-1144.
2. Soucie JM, De Staercke C, Monahan PE, Recht M, Chitlur MB, Gruppo R, Hooper WC, Kessler C, Kulkarni R, Manco-Johnson MJ, Powell J, Pyle M, Riske B, Sabio H, Trimble S, the US Hemophilia Treatment Center Network. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test (NAT) screening. Transfusion 2013. doi: 10.1111/j.1537-2995.2012.03907.x.
3. Geng Y, Wu C, Bhattacharyya SP, Tan D, Guo Z, Yu MW,. Parvovirus B19 in factor VIII concentrates; effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007; 47: 883-889.
4. Modrow S, Wenzel JJ, Schimanski S, Schwarzbeck J, Rothe U, Jilg W, Eis-Hubinger AM,. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Vox Sang 2011; 100: 351-358.
5. Norja P, Lassila R, Makris M,. Parvovirus transmission by blood products-a cause for concern? Br J Haematol 2012; 159: 385-393.